Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Deciphera Pharmaceuticals Inc (DCPH) USD0.01

Sell:$52.80 Buy:$52.81 Change: $1.42 (2.76%)
NASDAQ:1.00%
Market closed |  Prices as at close on 6 December 2019 | Switch to live prices |
Sell:$52.80
Buy:$52.81
Change: $1.42 (2.76%)
Market closed |  Prices as at close on 6 December 2019 | Switch to live prices |
Sell:$52.80
Buy:$52.81
Change: $1.42 (2.76%)
Market closed |  Prices as at close on 6 December 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Deciphera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing drugs to improve the lives of cancer patients. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib. Its proprietary kinase switch control inhibitor platform, inhibit the activation of kinases. DCC-2618, an orally administered kinase switch control inhibitor, for the treatment of gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, including glioblastoma multiforme (GBM), and other solid tumors driven by pan-KIT or PDGFR alpha. DCC-3014 is an orally administered, potent and highly selective inhibitor of colony stimulating factor receptor 1 (CSF1R). Rebastinib is an orally administered, potent and selective inhibitor of the TIE2 immunokinase. Rebastinib binds potently into the switch pocket of TIE2, stabilizing the inhibitory switch and displacing the activation switch to block TIE2 signaling.

Contact details

Address:
200 Smith St
WALTHAM
02451-0099
United States
Telephone:
+1 (781) 2096400
Website:
https://www.deciphera.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
DCPH
ISIN:
US24344T1016
Market cap:
$2.65 billion
Shares in issue:
51.04 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • James Bristol
    Independent Chairman of the Board
  • Steven Hoerter
    President, Chief Executive Officer, Director
  • Daniel Flynn
    Founder, Executive Vice President, Chief Scientific Officer
  • Thomas Kelly
    Chief Financial Officer, Executive Vice President, Treasurer
  • Stephen Ruddy
    Chief Technology Officer
  • Daniel Martin
    Chief Commercial Officer
  • Christopher Morl
    Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.